NRIX · Company research
Nurix Therapeutics, Inc. (NRIX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
21records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth? | Kymera Therapeutics is developing KT-621, an oral STAT6 degrader in phase IIb trials for atopic dermatitis and eosinophilic asthma. The company completed enrollment in the BROADEN2 study ahead of schedule with top-line data expected by end of 2026. Future growth depends on trial outcomes, regulatory approval, and successful commercialization. The company faces competition from Arvinas and Nurix in the protein degradation therapy space. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.333 | 1 |
| Nurix Therapeutics Insider Sold Shares Worth $528,528, According to a Recent SEC Filing - Yahoo Finance | Nurix Therapeutics Insider Sold Shares Worth $528,528, According to a Recent SEC Filing Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| A director proposes selling 22,583 Nurix Therapeutics (Nasdaq: NRIX) shares acquired by exercising options. - Stock Titan | A director proposes selling 22,583 Nurix Therapeutics (Nasdaq: NRIX) shares acquired by exercising options. Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| Nurix Therapeutics (NASDAQ:NRIX) Shares Climb 4.1% After Analyst Upgrade - MarketBeat | Nurix Therapeutics (NASDAQ:NRIX) Shares Climb 4.1% After Analyst Upgrade MarketBeat | View source ↗ | MarketBeat | Oct 14, 2026 | neutral | 0 | 0.6 |
| Nurix Therapeutics' Enterprise Value Remains Underappreciated, RBC Capital Markets Says - Yahoo Finance | Nurix Therapeutics' Enterprise Value Remains Underappreciated, RBC Capital Markets Says Yahoo Finance | View source ↗ | Yahoo Finance | Oct 13, 2026 | neutral | 0 | 0.6 |
| Nurix Therapeutics (NASDAQ:NRIX) Stock Price Target Cut by Truist Financial - MarketBeat | Nurix Therapeutics (NASDAQ:NRIX) Stock Price Target Cut by Truist Financial MarketBeat | View source ↗ | MarketBeat | Oct 13, 2026 | neutral | 0 | 0.6 |
| Nurix Therapeutics' (NRIX) Buy Rating Reiterated at Needham & Company LLC - MarketBeat | Nurix Therapeutics' (NRIX) Buy Rating Reiterated at Needham & Company LLC MarketBeat | View source ↗ | MarketBeat | Oct 13, 2026 | neutral | 0 | 0.6 |
| Nurix Therapeutics (NASDAQ:NRIX) Stock Price Expected to Rise, Robert W. Baird Analyst Says - MarketBeat | Nurix Therapeutics (NASDAQ:NRIX) Stock Price Expected to Rise, Robert W. Baird Analyst Says MarketBeat | View source ↗ | MarketBeat | Oct 13, 2026 | neutral | 0 | 0.6 |
| Nurix NRIX Reports $673.1 Million Revenue and $549.8 Million Third-Quarter Profit - Quiver Quantitative | Nurix NRIX Reports $673.1 Million Revenue and $549.8 Million Third-Quarter Profit Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 13, 2026 | neutral | 0 | 0.6 |
| Nurix Therapeutics, Inc. (NRIX) Free Cash Flow 2025: $263.5M outflow, down 44.9% - Stock Titan | Nurix Therapeutics, Inc. (NRIX) Free Cash Flow 2025: $263.5M outflow, down 44.9% Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| Nurix Therapeutics, Inc. (NRIX) Debt 2025 - Stock Titan | Nurix Therapeutics, Inc. (NRIX) Debt 2025 Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| Nurix Therapeutics, Inc. (NRIX) Stock Price, News, Quote & History - Yahoo! Finance Canada | Nurix Therapeutics, Inc. (NRIX) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 12, 2026 | neutral | 0 | 0.6 |
| Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates - Yahoo Finance | Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Oct 12, 2026 | neutral | 0 | 0.6 |
| Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates | Nurix Therapeutics reported Q3 2026 earnings of $4.73 per share, significantly beating the consensus estimate of a loss of $0.56 per share, with a 944.64% earnings surprise. Revenues reached $673.06 million, surpassing estimates by 383.11%. However, the stock received a Zacks Rank #3 (Hold) rating, with mixed estimate revisions and the company's industry ranking in the bottom 33% of sectors. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bearish | -0.5 | 1 |
| The first patient has joined a trial testing two drugs for a type of blood cancer. - Stock Titan | The first patient has joined a trial testing two drugs for a type of blood cancer. Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| Gilead's second cancer research extension brings Nurix a $10 million fee. - Stock Titan | Gilead's second cancer research extension brings Nurix a $10 million fee. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock? | Economic data shows mixed signals with softer-than-expected PCE inflation and stronger-than-expected Q2 GDP growth. Market attention is turning to Friday's employment report. Precigen shares surged 6.3% on growing investor confidence in sales of its FDA-approved drug Papzimeos for recurrent respiratory papillomatosis, with expected quarterly earnings up 181.8% year-over-year. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 0.5 | 1 |
| Nurix Therapeutics (NRIX) Starts Phase 3 And Lands Sanofi Milestone, Is The Valuation About Right? - Simply Wall Street | Nurix Therapeutics (NRIX) Starts Phase 3 And Lands Sanofi Milestone, Is The Valuation About Right? Simply Wall Street | View source ↗ | Simply Wall Street | Aug 18, 2026 | neutral | 0 | 0.6 |
| Nurix Therapeutics (NRIX) Stock Looks Expensive Even With A $31 Analyst Target - Yahoo Finance | Nurix Therapeutics (NRIX) Stock Looks Expensive Even With A $31 Analyst Target Yahoo Finance | View source ↗ | Yahoo Finance | Jun 16, 2026 | neutral | 0 | 0.6 |
| NRIX Stock Slides As Traders Parse Insider Filing - timothysykes.com | NRIX Stock Slides As Traders Parse Insider Filing timothysykes.com | View source ↗ | timothysykes.com | Jun 8, 2026 | neutral | 0 | 0.6 |
| Nurix Therapeutics, Inc. Common stock (NRIX) Stock Price: Oct 6 Close $22.60 - Gotrade | Nurix Therapeutics, Inc. Common stock (NRIX) Stock Price: Oct 6 Close $22.60 Gotrade | View source ↗ | Gotrade | Jan 13, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.